Mind Medicine (MindMed) (MNMD) News Today

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) News Summary

• Positive Sentiment: Analysts at HC Wainwright raised their FY2028 EPS estimate for MNMD to $0.37 from $0.30, pointing to improved long-term profitability expectations. HC Wainwright Has Positive Estimate for MNMD FY2028 Earnings
• Positive Sentiment: Could MNMD be a top buy for 2026? A recent MSN Money analysis highlights MindMed’s expanding clinical pipeline in psychedelic therapies and potential catalysts for growth next year. Could This Psychedelic Drug Stock Be a Top Buy for 2026?
• Neutral Sentiment: Oppenheimer initiates research coverage on MNMD, providing a fresh set of analyst perspectives without immediate EPS revisions. Mind Medicine (MindMed) Research Coverage Started at Oppenheimer
• Negative Sentiment: HC Wainwright cut its Q3 2025 EPS forecast for MNMD to ($0.51) from ($0.36), signaling near-term pressure on the biotech’s financial performance. HC Wainwright Has Negative Outlook for MNMD Q3 Earnings
• Negative Sentiment: Roth Capital reduced its Q3 2025 EPS estimate for MNMD to ($0.49) from ($0.39), reflecting increased skepticism around the company’s upcoming quarterly results. Roth Capital Brokers Reduce Earnings Estimates for MNMD
• Negative Sentiment: Roth Capital issued a pessimistic forecast for MNMD’s broader earnings outlook, underscoring concerns about the biotech’s near-term revenue prospects. Roth Capital Issues Pessimistic Forecast for MNMD Earnings